Advanced

Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

Bollerslev, J; Hallen, J; Fougner, KJ; Jorgensen, AP; Kristo, C; Fagertun, H; Gudmundsen, O; Burman, Pia LU and Schreiner, T (2005) In European Journal of Endocrinology 153(3). p.379-387
Abstract
Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body... (More)
Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body mass was increased by 1.8 +/- 2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Endocrinology
volume
153
issue
3
pages
379 - 387
publisher
Society of the European Journal of Endocrinology
external identifiers
  • pmid:16131600
  • wos:000232228400005
  • scopus:26244464919
ISSN
1479-683X
DOI
10.1530/eje.1.01971
language
English
LU publication?
yes
id
2c9b8755-fe8e-4178-be4a-b20a4d86b0de (old id 891546)
date added to LUP
2008-01-11 12:02:10
date last changed
2017-01-01 05:14:12
@article{2c9b8755-fe8e-4178-be4a-b20a4d86b0de,
  abstract     = {Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life QOL). GH and placebo were administered for 9 months each, separated, by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean lGF-I concentration at baseline was higher in men than in women(9 95 +/- 33 vs 68 +/- 41 mu g/l respectively; P &lt; 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9 +/- 2.9 kg and lean body mass was increased by 1.8 +/- 2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.},
  author       = {Bollerslev, J and Hallen, J and Fougner, KJ and Jorgensen, AP and Kristo, C and Fagertun, H and Gudmundsen, O and Burman, Pia and Schreiner, T},
  issn         = {1479-683X},
  language     = {eng},
  number       = {3},
  pages        = {379--387},
  publisher    = {Society of the European Journal of Endocrinology},
  series       = {European Journal of Endocrinology},
  title        = {Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial},
  url          = {http://dx.doi.org/10.1530/eje.1.01971},
  volume       = {153},
  year         = {2005},
}